<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Zollinger-Ellison syndrome (gastrinoma): Clinical manifestations and diagnosis
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Emily Bergsland, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark Feldman, MD, MACP, AGAF, FACG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Shilpa Grover, MD, MPH, AGAF
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zollinger-Ellison (ZES) syndrome is characterized by gastric acid hypersecretion resulting in severe acid-related peptic disease and diarrhea [
         <a href="#rid1">
          1,2
         </a>
         ]. The clinical manifestations and diagnosis of ZES will be reviewed here. The management of ZES is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">
          "Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zollinger-Ellison syndrome (ZES) is caused by secretion of gastrin by duodenal or pancreatic neuroendocrine tumors (gastrinomas). The annual incidence of gastrinomas is 0.5 to 2 per million population [
         <a href="#rid3">
          3-5
         </a>
         ]. Most patients are diagnosed between the ages of 20 and 50, with a higher incidence in males as compared with females [
         <a href="#rid6">
          6
         </a>
         ]. Approximately 80 percent of gastrinomas are sporadic, but 20 to 30 percent occur in association with multiple endocrine neoplasia type 1 (MEN1) [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
         Although gastrinomas are one of the most common functional pancreatic neuroendocrine tumors, only 20 to 25 percent of gastrinomas arise in the pancreas [
         <a href="#rid6">
          6,9
         </a>
         ]. Approximately 50 to 88 percent of patients with sporadic ZES, and 70 to 100 percent of patients with ZES associated with MEN1, have duodenal gastrinomas [
         <a href="#rid8">
          8
         </a>
         ]. Duodenal gastrinomas are predominantly found in the first part of the duodenum. As compared with pancreatic gastrinomas, duodenal gastrinomas are usually small (&lt;1 cm), are often multiple, and are less likely to have metastasized to the liver at diagnosis (0 to 10 versus 22 to 35 percent) [
         <a href="#rid6">
          6,7,10,11
         </a>
         ]. In 5 to 15 percent of patients, gastrinomas arise in non-pancreatic, non-duodenal abdominal (stomach, peripancreatic lymph nodes, liver, bile duct, ovary), and extra-abdominal (heart, small cell lung cancer) locations [
         <a href="#rid12">
          12-14
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h1">
          CLASSIFICATION, NOMENCLATURE, AND HISTOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The World Health Organization (WHO) classifies neuroendocrine tumors (NETs) arising within the digestive system based upon the extent to which they resemble their normal non-neoplastic counterparts  (
         <a class="graphic graphic_table graphicRef122325" href="/z/d/graphic/122325.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">
          "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on '2010 and 2019 World Health Organization classification'
         </a>
         .)
        </p>
        <p>
         Histologically, most gastrinomas are well-differentiated NETs with few mitoses and a histologic appearance that is similar to that of other pancreatic NETs. The cells are arranged in a solid, trabecular, gyriform, or glandular pattern, with fairly uniform nuclei, salt-and-pepper chromatin, and finely granular cytoplasm. As with other pancreatic NETs, the degree of malignancy cannot be predicted by morphologic appearance alone. The cells produce abundant neurosecretory granules, as reflected in the strong and diffuse immunohistochemical expression of neuroendocrine markers such as synaptophysin and chromogranin. Gastrin is the predominant peptide within the secretory granules of gastrinoma cells, but other neuroendocrine peptides such as vasoactive intestinal peptide and glucagon can sometimes be identified as well. The designation of the tumor as a gastrinoma is based upon the presence of a clinical syndrome that results from tumor production and secretion of gastrin, and not by its morphologic appearance or the presence of gastrin in the secretory granules. Of note, not all patients with ectopic gastrin secretion have the symptoms associated with Zollinger-Ellison syndrome, as in many cases, the hormone is not processed to biologically active gastrin [
         <a href="#rid15">
          15
         </a>
         ]. If a tumor stains for gastrin or secretes gastrin but does not produce symptoms of Zollinger-Ellison syndrome, it should not be considered a gastrinoma. (See
         <a class="medical medical_review" href="/z/d/html/14247.html" rel="external">
          "Pathology, classification, and grading of neuroendocrine neoplasms arising in the digestive system", section on 'Functionality and nomenclature'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H565716091">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Excessive gastrin secretion from a gastrinoma results in high gastric acid output (usually four- to sixfold, and up to over 10-fold) due to the trophic action of gastrin on parietal cells and histamine-secreting enterochromaffin-like (ECL) cells  (
         <a class="graphic graphic_picture graphicRef78549" href="/z/d/graphic/78549.html" rel="external">
          picture 1
         </a>
         ) [
         <a href="#rid15">
          15
         </a>
         ]. In addition, gastrin stimulates parietal cells largely via the release of histamine. (See
         <a class="medical medical_review" href="/z/d/html/33.html" rel="external">
          "Physiology of gastric acid secretion"
         </a>
         .)
        </p>
        <p>
         Chronic diarrhea in Zollinger-Ellison syndrome results from the following [
         <a href="#rid6">
          6
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The high volume of gastric acid secretion that cannot be fully reabsorbed by the small intestine and colon.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The rate of gastric acid secretion exceeds the neutralizing capacity of pancreatic bicarbonate secretion, resulting in an exceptionally low pH of intestinal contents. The low pH inactivates pancreatic digestive enzymes, interfering with the emulsification of fat by bile acids, and damaging intestinal epithelial cells and villi. Maldigestion and malabsorption both result in steatorrhea.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Extremely high serum gastrin concentrations inhibit the absorption of sodium and water by the small intestine, thereby adding a secretory component to the diarrhea.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H60295009">
         <span class="h2">
          Clinical presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Peptic ulcer disease (73 to 98 percent), heartburn (52 to 55 percent), diarrhea (60 to 75 percent), weight loss (7 to 53 percent), and complications from acid hypersecretion (bleeding, stricture, fistulization, perforation) are the most common symptoms in patients with Zollinger-Ellison syndrome (ZES)  (
         <a class="graphic graphic_figure graphicRef82168" href="/z/d/graphic/82168.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid15">
          15,16
         </a>
         ]. Sixty to ninety percent of gastrinomas are malignant [
         <a href="#rid8">
          8
         </a>
         ]. The mean time to diagnosis is six years [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
         Approximately 1 to 10 percent of patients, especially with metastatic disease or multiple endocrine neoplasia type 1 (MEN1), have symptoms due to a second hormonal syndrome (eg, VIPoma, somatostatinoma, glucagonoma, ACTH) [
         <a href="#rid17">
          17
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/143.html" rel="external">
          "Epidemiology and clinical manifestations of Cushing syndrome", section on 'Frequency and severity of symptoms'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2608.html" rel="external">
          "Somatostatinoma: Clinical manifestations, diagnosis, and management", section on 'Clinical manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2610.html" rel="external">
          "VIPoma: Clinical manifestations, diagnosis, and management", section on 'Clinical features'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2611.html" rel="external">
          "Glucagonoma and the glucagonoma syndrome", section on 'Clinical features'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17088667">
         <span class="h2">
          Endoscopic features
         </span>
         <span class="headingEndMark">
          —
         </span>
         Over 90 percent of patients with ZES develop peptic ulcers [
         <a href="#rid18">
          18
         </a>
         ]. Patients with ZES, like those with sporadic peptic ulcer disease, often present with solitary ulcers less than 1 cm in diameter. Approximately 75 percent of ulcers are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum [
         <a href="#rid19">
          19
         </a>
         ]. Ulcers are more likely to be refractory to proton pump inhibitor therapy and to recur as compared with patients with sporadic ulcer disease. Furthermore, in ZES, ulcers often occur in unusual locations (eg, beyond the first or second fold of the duodenum). Over 90 percent of patients with ZES often have prominent gastric folds. Patients may also have evidence of reflux esophagitis [
         <a href="#rid20">
          20
         </a>
         ]. However, strictures of the esophagus, pylorus, or duodenum are present in less than 10 percent of patients [
         <a href="#rid16">
          16
         </a>
         ]. In the setting of MEN1, duodenal gastrinomas are typically multifocal, small (&lt;0.5 cm), and associated with lymph node involvement in 40 to 60 percent [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Zollinger-Ellison syndrome (ZES) should be suspected in patients with multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea, enlarged gastric folds, or multiple endocrine neoplasia type 1 (MEN1)  (
         <a class="graphic graphic_table graphicRef50291" href="/z/d/graphic/50291.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ]. ZES should also be suspected in patients with peptic ulcer disease and a family history of peptic ulcer disease or MEN1, or in patients with diarrhea that is responsive to proton pump inhibitors (PPIs). The diagnosis is established by demonstrating an elevated basal or stimulated gastrin concentration (in the setting of a low gastric pH).
        </p>
        <p class="headingAnchor" id="H565716279">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initial evaluation in a patient with suspected ZES is with measurement of fasting serum gastrin concentration and measurement of gastric pH. In patients with elevated gastrin levels/low gastric pH that are not diagnostic for ZES, we perform a
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         stimulation test. The calcium infusion study (intravenous infusion with
         <a class="drug drug_general" data-topicid="9190" href="/z/d/drug information/9190.html" rel="external">
          calcium gluconate
         </a>
         ) is usually reserved for patients with gastric acid hypersecretion in whom there is a strong clinical suspicion of gastrinoma despite a negative secretin stimulation test [
         <a href="#rid22">
          22
         </a>
         ]. Importantly, the diagnosis of ZES can be difficult to make, as evidenced by the fact the average time from onset of symptoms to diagnosis is &gt;5 years. The symptoms can be nonspecific and/or masked by PPI use [
         <a href="#rid23">
          23
         </a>
         ]. Gastric antral/body biopsy for atrophic gastritis combined with parietal cell and intrinsic factor antibodies can also be useful for confirming situations of "appropriate" hypergastrinemia.
        </p>
        <p>
         In patients in whom PPIs cannot safely be stopped, modern criteria for ZES have been proposed [
         <a href="#rid8">
          8
         </a>
         ]. An elevated gastrin level, combined with a history of current or recent peptic ulcer disease, and improvement of diarrhea on a PPI supports a diagnosis of ZES, particularly in the setting of a positive biopsy for a well differentiated neuroendocrine tumor (in a patient with or without MEN1). The diagnosis is less clear without a tissue diagnosis and with only a history of positive somatostatin receptor imaging (with or without MEN1).
        </p>
        <p>
         In patients with a positive imaging study and fasting hypergastrinemia without peptic ulcer disease or diarrhea, a lack of atrophic gastritis and the absence of parietal cell and intrinsic factor antibodies suggests gastrinoma. However, it is important to note that atrophic gastritis can be missed with this approach as detection depends on biopsy location and number, and parietal cell and intrinsic factor antibodies are not always positive.
        </p>
        <p>
         Furthermore, the use of somatostatin imaging (eg, 68Ga-DOTATATE positron emission tomography [PET]/computed tomography [CT] or 111In-DTPA-octreotide with single-photon emission CT [SPECT]/CT) for diagnosis is of limited value, as it can detect any benign or malignant process overexpressing somatostatin receptors, and there can be uptake in nonneoplastic conditions like arthritis, infections, thyroid disease, granulomatous diseases [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Serum gastrin concentration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Fasting serum gastrin should be measured in any patient suspected of having ZES [
         <a href="#rid6">
          6
         </a>
         ]. A serum gastrin value greater than 10 times the upper limit of normal (1000 pg/mL) in the presence of a gastric pH below 2 is diagnostic of ZES. Higher levels are more likely with pancreatic (compared with duodenal) tumors, larger tumor size, and with metastatic disease [
         <a href="#rid6">
          6
         </a>
         ]. Measurement of gastric pH on a single specimen is important to exclude secondary hypergastrinemia due to achlorhydria (eg, atrophic gastritis, pangastritis-associated
         <em>
          Helicobacter pylori
         </em>
         infections, renal failure, vagotomy, and ingestion of gastric acid antisecretory drugs [eg, PPIs]). In such cases the serum gastrin level can exceed 1000 pg/mL, but the gastric pH is &gt;2. Importantly, these "appropriate" hypergastrinemic conditions are much more common and need to be distinguished from inappropriate causes, such as ZES [
         <a href="#rid8">
          8
         </a>
         ]. While assessment of gastric pH is classically required for the diagnosis of ZES, case series suggest that assessment of gastric acidity is underutilized. This is likely due to the inability to stop PPIs or unfamiliarity with gastric pH testing).
        </p>
        <p>
         Approximately two-thirds of patients with ZES have serum gastrin concentrations less than 10 times the upper limit of normal (between 110 and 1000 pg/mL) [
         <a href="#rid6">
          6
         </a>
         ]. This degree of hypergastrinemia is nonspecific and can also be present in patients with increased gastric acid secretion (eg, antral G-cell hyperplasia, gastric outlet obstruction, and retained gastric antrum). Patients receiving PPIs generally have elevated serum gastrin levels. Fasting serum gastrin levels can fluctuate even within the same patient, and elevated levels should be rechecked (see
         <a class="local">
          'Differential diagnosis'
         </a>
         below). Importantly, no level of hypergastrinemia can distinguish appropriate from inappropriate hypergastrinemia; high levels can be seen in the setting of atrophic gastritis or PPI use [
         <a href="#rid8">
          8
         </a>
         ]. However, persistently normal fasting serum gastrin values are exceedingly uncommon in ZES [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         Commercial immunoassay kits in current use vary in their accuracy [
         <a href="#rid23">
          23,24
         </a>
         ]. In one study that evaluated 12 different commercial assay kits, four of the kits returned falsely low results in 20 to 80 percent of patients [
         <a href="#rid24">
          24
         </a>
         ]. False negatives are most likely to occur at relatively low gastrin concentrations, with most assays accurately detecting patients with ZES whose serum gastrin concentrations are greater than 400 pmol/L (845 pg/mL).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Secretin stimulation test
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         stimulation test is used to differentiate patients with gastrinomas from other causes of hypergastrinemia (eg, in the setting of gastrin, &lt;10-fold upper limit of normal and gastric pH ≤2). Although, some have questioned the test’s utility since achlorhydria can lead to false positives [
         <a href="#rid8">
          8
         </a>
         ]. Secretin stimulates the release of gastrin by gastrinoma cells, and patients with ZES tumors have a dramatic rise in serum gastrin. In contrast, normal gastric G cells are inhibited by secretin.
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         test should not be performed in a patient on PPIs. False-negative responses have been reported in 6 to 20 percent of patients [
         <a href="#rid25">
          25
         </a>
         ]. However, other studies suggest that false-negative results caused by PPIs may be low in frequency, particularly in patients with a high pretest probability of ZES [
         <a href="#rid26">
          26
         </a>
         ]. False-positive results occurred in 15 to 39 percent of patients with achlorhydria induced by PPIs or due to chronic atrophic gastritis [
         <a href="#rid27">
          27
         </a>
         ]. However, if PPIs are discontinued abruptly, patients with ZES are at high risk to develop complications (such as acute bleeding and perforation) during the interim week [
         <a href="#rid28">
          28
         </a>
         ]. As such, discontinuation of a PPI in a patient suspected of having ZES should be done by an experienced provider. Before this is attempted, an endoscopy should be performed to exclude active ulcer disease. If ulceration is present, suppressive PPI therapy should be used until active disease is healed before stopping PPI therapy [
         <a href="#rid8">
          8
         </a>
         ]. One week prior to the secretin study we substitute PPIs with high-dose H2 receptor antagonists (eg,
         <a class="drug drug_general" data-topicid="9265" href="/z/d/drug information/9265.html" rel="external">
          cimetidine
         </a>
         300 to 600 mg every six hours) until 12 to 30 hours prior to the test [
         <a href="#rid8">
          8
         </a>
         ]. Oral antacids are then taken as needed until midnight prior to the study. Patients should be advised to seek immediate medical attention for nasogastric aspiration if they develop significant exacerbation of ZES symptoms (eg, vomiting, pain, diarrhea) during the taper period [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         stimulation test is performed by administering 0.4 micrograms/kg by rapid infusion intravenously over one minute; a baseline fasting serum gastrin is measured twice before the secretin is administered and 2, 5, and 10 minutes later. Several criteria have been proposed to define a positive test; an increase in gastrin levels of greater than 120 pg/mL over basal fasting levels has a sensitivity and a specificity of 94 and 100 percent, respectively (others use an absolute increase greater than 110 or 200 pg/mL, or a 50 percent increase in gastrin levels) [
         <a href="#rid22">
          22,23,30
         </a>
         ]. Serum gastrin levels usually peak by 10 minutes  (
         <a class="graphic graphic_figure graphicRef66223" href="/z/d/graphic/66223.html" rel="external">
          figure 2
         </a>
         ).
        </p>
        <p>
         The
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         stimulation test should not be performed in patients with active severe manifestations of ZES. This includes patients with severe abdominal pain, vomiting and diarrhea to the point of dehydration, or endoscopic findings of thickened gastric folds or multiple ulcers, as they are at particular risk for life-threatening consequences of discontinuing acid suppression. In such patients, tumor localization studies should be performed. (See
         <a class="local">
          'Tumor localization'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H17088817">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other tests that are supportive of the diagnosis of ZES but are less commonly performed include the following [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serum chromogranin A
         </strong>
         – Serum chromogranin A is elevated in most patients with gastrinomas, and the level of elevation tends to correlate with tumor volume [
         <a href="#rid31">
          31
         </a>
         ]. In contrast to other neuroendocrine tumors, very high levels of chromogranin A can be seen in gastrinomas without liver metastases [
         <a href="#rid32">
          32
         </a>
         ]. Chromogranin A levels are usually normal or near normal in patients with high gastrin levels secondary to chronic atrophic gastritis. (See
         <a class="medical medical_review" href="/z/d/html/2613.html" rel="external">
          "Clinical characteristics of well-differentiated neuroendocrine (carcinoid) tumors arising in the gastrointestinal and genitourinary tracts", section on 'Stomach'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, serum chromogranin A is less sensitive for a gastrinoma as compared with fasting serum gastrin levels. In addition, elevated chromogranin A is not specific to gastrinomas and is a general marker for well-differentiated neuroendocrine tumors [
         <a href="#rid33">
          33
         </a>
         ]. Elevated chromogranin A levels may be seen in a number of other conditions including PPI use [
         <a href="#rid34">
          34,35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Gastric acid secretion studies
         </strong>
         – Gastric acid secretion studies to measure basal acid output, which were once pivotal in establishing the diagnosis of ZES, are no longer performed due to their technical difficulty [
         <a href="#rid27">
          27
         </a>
         ]. Basal acid output is measured by the passage of a nasogastric tube into the dependent portion of the stomach with aspiration and quantification of gastric juice production over a one-hour period. A basal acid output of &gt;15 mEq/hour is supportive of the diagnosis of ZES.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H60295066">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Antral G-cell hyperplasia
         </strong>
         – Antral G-cell hyperplasia is a rare entity associated with increase in the number of G cells and characterized by a marked hypergastrinemia. Peptic ulcers can also be seen in patients with antral G-cell hyperplasia. However, unlike Zollinger Ellison syndrome (ZES), antral G-cell hyperplasia is characterized by a poor response to
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         stimulation test, and absence of gastrinoma on imaging.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Retained antrum syndrome
         </strong>
         – Retained antrum syndrome should be suspected in patients with
         <strong>
         </strong>
         recurrent peptic ulceration after gastrectomy. In such cases, peptic ulcer recurrence results from incomplete excision of the gastric antrum from the duodenum. Gastrin elevation in patients with retained antrum syndrome is only modest as compared with patients with ZES, and hypergastrinemia is reversible with excision of the retained antral remnant.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          TUMOR LOCALIZATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the diagnosis of Zollinger-Ellison syndrome (ZES) is made, the gastrinoma must be located and staged. (See
         <a class="medical medical_review" href="/z/d/html/2584.html" rel="external">
          "Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">
          "Multiple endocrine neoplasia type 1: Management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor localization begins with an upper endoscopy if not already performed, cross-sectional imaging with helical, contrast-enhanced, triple-phase computed tomography (CT) or magnetic resonance imaging (MRI), and somatostatin receptor-based imaging (somatostatin receptor scintigraphy [SRS]) using 111-In pentetreotide, or integrated PET/CT using Gallium-68-DOTA-0-Phe
         <sup>
          1
         </sup>
         -Tyr
         <sup>
          3
         </sup>
         -Octreotate (
         <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">
          Gallium Ga-68 DOTATATE
         </a>
         ) or Gallium-68-DOTA-0-Phe
         <sup>
          1
         </sup>
         -Tyr
         <sup>
          3
         </sup>
         -Octreotide (Gallium Ga-68 DOTATOC) [
         <a href="#rid36">
          36,37
         </a>
         ]. Because of its greater sensitivity, Ga-68 DOTATATE or Ga-68 DOTATOC PET imaging may be preferable to conventional SRS with 111-In pentetreotide [
         <a href="#rid38">
          38,39
         </a>
         ]. (See
         <a class="local">
          'Endoscopic features'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Somatostatin-receptor-based imaging'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If CT/MRI and somatostatin receptor-based imaging are negative, and surgery is being considered, an endoscopic ultrasound (EUS) should be performed because of its greater sensitivity in detecting small tumors. EUS also permits fine-needle aspiration for histological identification. (See
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Endoscopic ultrasonography'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We reserve invasive testing to localize the tumor with angiography or selective arterial stimulation and venous sampling with
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         injection for patients who are strongly suspected of having a gastrinoma in whom imaging is negative [
         <a href="#rid40">
          40
         </a>
         ]. The sensitivity for pancreas tumors is 75 to 100 percent, and the specificity is 95 percent; the sensitivity for duodenal tumors is 38 to 63 percent [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         However, in some cases tumor localization can only be achieved at laparotomy by direct palpation, duodenal transillumination, or intraoperative ultrasound. (See
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Intraoperative localization techniques'
         </a>
         and
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          STAGING SYSTEM
         </span>
         <span class="headingEndMark">
          —
         </span>
         Two staging systems are available for pancreatic neuroendocrine tumors such as gastrinomas, one from the combined American Joint Committee on Cancer/Union for International Cancer Control (UICC) [
         <a href="#rid41">
          41
         </a>
         ], and another proposed by the European Neuroendocrine Tumor Society  (
         <a class="graphic graphic_table graphicRef86409" href="/z/d/graphic/86409.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid41">
          41,42
         </a>
         ]. Both staging systems are highly prognostic for both relapse-free and overall survival [
         <a href="#rid43">
          43-45
         </a>
         ]. The newest update of the TNM staging classification (8
         <sup>
          th
         </sup>
         edition, 2017) has a staging system for neuroendocrine tumors of the pancreas  (
         <a class="graphic graphic_table graphicRef111355" href="/z/d/graphic/111355.html" rel="external">
          table 4
         </a>
         ) that is separate from that used for exocrine pancreatic tumors [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2612.html" rel="external">
          "Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine neoplasms", section on 'Staging system'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H492533011">
         <span class="h1">
          ADDITIONAL EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest biochemical studies to screen for multiple endocrine neoplasia type 1 (MEN1) in patients with Zollinger-Ellison syndrome (ZES), as 20 to 25 percent of patients have MEN1 and because up to 40 percent of MEN1/ZES patients have no family history [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with ZES should have serum parathormone levels, ionized calcium levels, and prolactin levels at diagnosis and periodically thereafter [
         <a href="#rid13">
          13
         </a>
         ]. Screening for MEN1-associated tumors is discussed separately. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Monitoring for MEN1-associated tumors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Individuals with a family history of MEN1, suspicious clinical or laboratory findings (eg, renal colic or nephrolithiases, history of hypercalcemia), or multiple MEN1 tumor types (parathyroid gland, anterior pituitary, and enteropancreatic) should undergo evaluation for MEN1 syndrome. The management of patients with MEN1 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2026.html" rel="external">
          "Multiple endocrine neoplasia type 1: Management"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with gastrinoma should at least be considered for testing for an inherited genetic syndrome. Data suggest that 17 percent of patients with seemingly sporadic pancreatic neuroendocrine tumors harbor germline alterations in any one of a variety of genes (including
         <em>
          MUTYH, CHEK2
         </em>
         , and
         <em>
          BRCA2
         </em>
         , as well as
         <em>
          MEN1
         </em>
         and
         <em>
          VHL
         </em>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H918065194">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/111962.html" rel="external">
          "Society guideline links: Well-differentiated gastroenteropancreatic neuroendocrine tumors"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Zollinger-Ellison syndrome (ZES) is caused by secretion of gastrin by duodenal or pancreatic neuroendocrine tumors (gastrinomas). The annual incidence of gastrinomas is 0.5 to 2 per million population. Most patients are diagnosed between the ages of 20 and 50, with a higher incidence in males as compared with females. While most gastrinomas are sporadic, 20 to 30 percent occur in association with multiple endocrine neoplasia type 1 (MEN1) syndrome. Approximately 50 to 88 percent of sporadic ZES patients, and 70 to 100 percent of ZES and MEN1, have duodenal gastrinomas. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Classification, nomenclature, and histology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive gastrin secretion from a gastrinoma results in high gastric acid output. Chronic diarrhea results from failure of resorption of the increased gastric acid, inactivation of pancreatic enzymes, damage to intestinal epithelium, and inhibition of the absorption of sodium and water. (See
         <a class="local">
          'Classification, nomenclature, and histology'
         </a>
         above and
         <a class="local">
          'Pathophysiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Abdominal pain (75 percent) and diarrhea (73 percent) are the most common symptoms in patients with ZES. Nearly half of patients have heartburn due to gastroesophageal reflux  (
         <a class="graphic graphic_figure graphicRef82168" href="/z/d/graphic/82168.html" rel="external">
          figure 1
         </a>
         ). Other symptoms include weight loss (17 percent) and gastrointestinal bleeding (25 percent). (See
         <a class="local">
          'Clinical presentation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Over 90 percent of patients with ZES develop peptic ulcers. Patients with ZES often present with solitary ulcers less than 1 cm in diameter. Approximately 75 percent of ulcers are in the first portion of the duodenum, 14 percent in the distal duodenum, and 11 percent in the jejunum. Ulcers in ZES may be refractory to proton pump inhibitors and recur much more often as compared with patients with sporadic ulcer disease. On upper endoscopy, patients with ZES may have prominent gastric folds and evidence of reflux esophagitis. However, strictures of the esophagus, pylorus, or duodenum are present in less than 10 percent of patients. (See
         <a class="local">
          'Endoscopic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ZES should be suspected in patients with multiple or refractory peptic ulcers; ulcers distal to the duodenum; peptic ulcer disease and diarrhea, enlarged gastric folds, an endocrinopathy or MEN1  (
         <a class="graphic graphic_table graphicRef50291" href="/z/d/graphic/50291.html" rel="external">
          table 2
         </a>
         ). ZES should also be suspected in patients with peptic ulcer disease and a family history of peptic ulcer disease or MEN1. The diagnosis is established by demonstrating an elevated basal or stimulated gastrin concentration, ideally assessed off a PPI (if safe) and in the setting of a gastric pH &lt;2. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tumor localization begins with an upper endoscopy if not already performed, cross-sectional imaging with helical, contrast-enhanced, triple-phase computed tomography (CT) or magnetic resonance imaging (MRI), and somatostatin receptor-based imaging using somatostatin receptor scintigraphy (SRS) with 111-In pentetreotide or integrated PET/CT using
         <a class="drug drug_general" data-topicid="108440" href="/z/d/drug information/108440.html" rel="external">
          Gallium Ga-68 DOTATATE
         </a>
         or Ga-68 DOTATOC. Because of its greater sensitivity, Ga-68 DOTATATE or Ga-68 DOTATOC PET/CT is preferred over conventional SRS with 111-In pentetreotide, where available. If CT or MRI and somatostatin receptor-based imaging are negative, and surgery is being considered, endoscopic ultrasound should be performed to localize the tumor. We reserve invasive testing to localize the tumor with angiography or selective arterial stimulation and venous sampling with
         <a class="drug drug_general" data-topicid="10259" href="/z/d/drug information/10259.html" rel="external">
          secretin
         </a>
         injection for patients who are strongly suspected of having a gastrinoma in whom imaging is negative. However, in some cases, tumor localization can only be achieved at laparotomy, by direct palpation, duodenal transillumination, or intraoperative ultrasound. (See
         <a class="local">
          'Tumor localization'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         All patients with gastrinoma should at least be considered for testing for inherited genetic syndromes. Approximately 20 to 30 percent of patients develop ZES in the setting of MEN1 syndrome. As such, all patients with ZES should be screened for MEN1 syndrome with serum parathormone levels, ionized calcium levels, and prolactin levels at diagnosis, and periodically thereafter. Individuals with a family history of MEN1, suspicious clinical or laboratory findings (eg, renal colic or nephrolithiases, history of hypercalcemia), or multiple MEN1 tumor types (parathyroid gland, anterior pituitary, and enteropancreatic) should undergo evaluation for MEN1 syndrome. (See
         <a class="local">
          'Additional evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2039.html" rel="external">
          "Multiple endocrine neoplasia type 1: Clinical manifestations and diagnosis", section on 'Diagnosis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1092278720">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Dr. Stephen E. Goldfinger, MD, for his past contributions as an author to previous versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           ZOLLINGER RM, ELLISON EH. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann Surg 1955; 142:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellison EC, Johnson JA. The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations. Curr Probl Surg 2009; 46:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulke MH, Anthony LB, Bushnell DL, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39:735.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oberg K. Pancreatic endocrine tumors. Semin Oncol 2010; 37:594.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berna MJ, Hoffmann KM, Serrano J, et al. Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 2006; 85:295.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA. Neuroendocrine tumors of the pancreas and duodenum. Curr Probl Surg 1994; 31:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz DC, Cadiot G, Poitras P, et al. Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing. Int J Endocr Oncol 2017; 4:167.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isenberg JI, Walsh JH, Grossman MI. Zollinger-Ellison syndrome. Gastroenterology 1973; 65:140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhuang Z, Vortmeyer AO, Pack S, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res 1997; 57:4682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weber HC, Venzon DJ, Lin JT, et al. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 1995; 108:1637.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA, Alexander HR, Fraker DL, et al. Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study. Ann Surg 2003; 237:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen RT, Cadiot G, Brandi ML, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012; 95:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA, Foster DS, Blumgart LH, et al. Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract. JAMA Surg 2018; 153:e175083.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am 2018; 47:577.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore) 2000; 79:379.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mestier L, Hentic O, Cros J, et al. Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study. Ann Intern Med 2015; 162:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deveney CW, Deveney KE. Zollinger-Ellison syndrome (gastrinoma). Current diagnosis and treatment. Surg Clin North Am 1987; 67:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meko JB, Norton JA. Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 1995; 46:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Venkat PG, Longstreth GF. Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome. Am J Gastroenterol 2022; 117:1012.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orloff SL, Debas HT. Advances in the management of patients with Zollinger-Ellison syndrome. Surg Clin North Am 1995; 75:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berna MJ, Hoffmann KM, Long SH, et al. Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features. Medicine (Baltimore) 2006; 85:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mendelson AH, Donowitz M. Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome. Dig Dis Sci 2017; 62:2258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rehfeld JF, Gingras MH, Bardram L, et al. The Zollinger-Ellison syndrome and mismeasurement of gastrin. Gastroenterology 2011; 140:1444.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuiper P, Biemond I, Masclee AA, et al. Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls. Pancreatology 2010; 10:14.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bhattacharya S, Blau JE, Cochran C, et al. Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome. Am J Gastroenterol 2021; 116:2216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah P, Singh MH, Yang YX, Metz DC. Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome. Pancreas 2013; 42:932.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poitras P, Gingras MH, Rehfeld JF. The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment. Clin Gastroenterol Hepatol 2012; 10:199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Metz DC. Diagnosis of the Zollinger–Ellison syndrome. Clin Gastroenterol Hepatol 2012; 10:126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79:1324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nobels FR, Kwekkeboom DJ, Coopmans W, et al. Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones. J Clin Endocrinol Metab 1997; 82:2622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tomassetti P, Migliori M, Simoni P, et al. Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur J Gastroenterol Hepatol 2001; 13:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Modlin IM, Gustafsson BI, Moss SF, et al. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease. Ann Surg Oncol 2010; 17:2427.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanduleanu S, Stridsberg M, Jonkers D, et al. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study. Aliment Pharmacol Ther 1999; 13:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giusti M, Sidoti M, Augeri C, et al. Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man. Eur J Endocrinol 2004; 150:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deppen SA, Liu E, Blume JD, et al. Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. J Nucl Med 2016; 57:708.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sadowski SM, Neychev V, Millo C, et al. Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites. J Clin Oncol 2016; 34:588.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Srirajaskanthan R, Kayani I, Quigley AM, et al. The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med 2010; 51:875.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med 2018; 59:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thom AK, Norton JA, Doppman JL, et al. Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas. Surgery 1992; 112:1002.
          </a>
         </li>
         <li class="breakAll">
          AJCC (American Joint Committee on Cancer) Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York  Vol 2010, p.241.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rindi G, Klöppel G, Alhman H, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strosberg JR, Cheema A, Weber JM, et al. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256:321.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Strosberg JR, Cheema A, Weber J, et al. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29:3044.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cho JH, Ryu JK, Song SY, et al. Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea. Pancreas 2016; 45:941.
          </a>
         </li>
         <li class="breakAll">
          Bergsland EK, Woltering EA, Rindo G. Neuroendocrine tumors of the pancreas. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.407. Corrected at 4th printing, 2018.
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2627 Version 28.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13259432" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19059523" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The Zollinger-Ellison syndrome: a comprehensive review of historical, scientific, and clinical considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20664472" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18703061" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21167379" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pancreatic endocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108778" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Serum gastrin in Zollinger-Ellison syndrome: I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7904550" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Neuroendocrine tumors of the pancreas and duodenum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29326808" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diagnosis of Zollinger-Ellison syndrome in the era of PPIs, faulty gastrin assays, sensitive imaging and limited access to acid secretory testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4354624" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Zollinger-Ellison syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9354421" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7768367" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12724631" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Possible primary lymph node gastrinoma: occurrence, natural history, and predictive factors: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22261919" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29365025" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Incidence and Prognosis of Primary Gastrinomas in the Hepatobiliary Tract.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30098717" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Gastrinomas: Medical or Surgical Treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11144036" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Zollinger-Ellison syndrome. Clinical presentation in 261 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25984844" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Metachronous hormonal syndromes in patients with pancreatic neuroendocrine tumors: a case-series study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2882614" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Zollinger-Ellison syndrome (gastrinoma). Current diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7598474" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of patients with Zollinger-Ellison syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35347099" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gastroesophageal Reflux Disease and the Zollinger-Ellison Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7747256" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Advances in the management of patients with Zollinger-Ellison syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17108779" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serum gastrin in Zollinger-Ellison syndrome: II. Prospective study of gastrin provocative testing in 293 patients from the National Institutes of Health and comparison with 537 cases from the literature. evaluation of diagnostic criteria, proposal of new criteria, and correlations with clinical and tumoral features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28776139" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Catching the Zebra: Clinical Pearls and Pitfalls for the Successful Diagnosis of Zollinger-Ellison Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21315717" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The Zollinger-Ellison syndrome and mismeasurement of gastrin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20299818" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Diagnostic efficacy of the secretin stimulation test for the Zollinger-Ellison syndrome: an intra-individual comparison using different dosages in patients and controls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34515664" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Validity of Secretin Stimulation Testing on Proton Pump Inhibitor Therapy for Diagnosis of Zollinger-Ellison Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23851430" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Hypochlorhydria and achlorhydria are associated with false-positive secretin stimulation testing for Zollinger-Ellison syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21871248" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : The Zollinger-Ellison syndrome: dangers and consequences of interrupting antisecretory treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21806955" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Diagnosis of the Zollinger–Ellison syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7439637" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Secretin injection test in the diagnosis of gastrinoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9253344" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the alpha-subunit of glycoprotein hormones.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11204811" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Diagnostic value of plasma chromogranin A in neuroendocrine tumours.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20217257" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10102943" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15012614" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Effect of short-term treatment with low dosages of the proton-pump inhibitor omeprazole on serum chromogranin A levels in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26769865" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26712231" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20484441" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The role of 68Ga-DOTATATE PET in patients with neuroendocrine tumors and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29025982" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1455303" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1455303" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Prospective study of the use of intraarterial secretin injection and portal venous sampling to localize duodenal gastrinomas.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16967267" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22415420" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21709192" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26765964" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Prognostic Validity of the American Joint Committee on Cancer and the European Neuroendocrine Tumors Staging Classifications for Pancreatic Neuroendocrine Tumors: A Retrospective Nationwide Multicenter Study in South Korea.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
